Browse TMC2

Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Note=Localized to the stereocilia of the cochlear hair cells.
Domain PF07810 TMC domain
Function

Probable ion channel required for the normal function of cochlear hair cells (PubMed:11850618). Component of the hair cell's mechanotransduction (MET) machinery. Involved in mechanosensitive responses of the hair cells (By similarity).

> Gene Ontology
 
Biological Process GO:0006816 calcium ion transport
GO:0007605 sensory perception of sound
GO:0009581 detection of external stimulus
GO:0009582 detection of abiotic stimulus
GO:0009612 response to mechanical stimulus
GO:0050910 detection of mechanical stimulus involved in sensory perception of sound
GO:0050954 sensory perception of mechanical stimulus
GO:0050974 detection of mechanical stimulus involved in sensory perception
GO:0050982 detection of mechanical stimulus
GO:0060004 reflex
GO:0060005 vestibular reflex
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0072511 divalent inorganic cation transport
Molecular Function GO:0005216 ion channel activity
GO:0005244 voltage-gated ion channel activity
GO:0005245 voltage-gated calcium channel activity
GO:0005261 cation channel activity
GO:0005262 calcium channel activity
GO:0015085 calcium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022832 voltage-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0022843 voltage-gated cation channel activity
GO:0046873 metal ion transmembrane transporter activity
GO:0072509 divalent inorganic cation transmembrane transporter activity
Cellular Component GO:0032420 stereocilium
GO:0032421 stereocilium bundle
GO:0032426 stereocilium tip
GO:0098858 actin-based cell projection
GO:0098862 cluster of actin-based cell projections
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TMC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TMC2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TMC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.270.615
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3560.771
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1610.911
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0380.88
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TMC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TMC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TMC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TMC2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TMC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TMC2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TMC2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTMC2
Nametransmembrane channel-like 2
Aliases dJ686C3.3; C20orf145; transmembrane, cochlear expressed, 2; transmembrane cochlear-expressed gene 2; transme ......
Chromosomal Location20p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TMC2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.